This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

October 1, 2023

Conditions
Relapsed/Refractory B-cell Malignancies
Interventions
DRUG

MH048

Soft gel capsules 5 mg and 25 mg,oral MH048 should be administered after an overnight fast.

Trial Locations (1)

310003

RECRUITING

the First Affiliated Hospita,Medicine School of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Minghui Pharmaceutical (Shanghai) LTD

INDUSTRY